What is Mektovi used to treat?
Medically reviewed by Drugs.com. Last updated on Aug 13, 2020.
Mektovi is used to treat patients with unresectable or metastatic melanoma (skin cancer that has spread) with a BRAF V600E or V600K gene mutation, as detected by an FDA-approved test.
Mektovi (binimetinib) from Array BioPharma, along with Braftovi (encorafenib), is part of an oral BRAF/MEK inhibitor combination therapy. Both Braftovi and Mektovi are kinase inhibitors.
Roughly 50% of patients diagnosed with metastatic melanoma test positive for the BRAF mutation, and it is the most common genetic mutation in metastatic melanoma.
Related Medical Questions
- What type of drug is Libtayo?
- How does Odomzo work?
- What is Braftovi used to treat?
- What is the difference between Opdivo and Keytruda?
- Pembrolizumab vs. nivolumab: how do they compare?
- What happens when you stop taking Opdivo for melanoma?
- What is the cost of Tecentriq?
- What type of cancer is Tecentriq used to treat?